R&D

Inefficient management of chronic pain costs Europe billions of Euros each year

A new report launched in the European Parliament shows inefficiencies in the treatment of chronic pain result in increasing healthcare costs and prolonged patient suffering.[1] Chronic pain costs Europe billions of Euros every year, with national costs ranging from €1.1 billion to nearly €50 billion.2,3 21% of Europeans with chronic pain are unable to work at all as a result of their chronic pain,[4] and of those able to work, 61% said it had impacted directly on their employment status.[4]

EU-funded study offers hope for stroke sufferers

An international team of researchers has come up with a novel way of treating strokes by blocking the activity of an enzyme responsible for much of the damage caused to brain cells in the period following a stroke. The findings represent a major step forward in the search for new treatments for ischemic stroke, which is the second leading cause of death worldwide.

First DataBank Signs Major New Contract with BT

First DataBank, the UK's leading provider of drug knowledge bases and active clinical decision support, has been awarded a contract by BT for its Multilex Drug Data File (Multilex DDF). This will be incorporated into CSE Healthcare Systems', RiO electronic patient record system which BT is installing at community and mental health trusts in London and the south of England as part of the NHS National Programme for Information Technology.

European pharmacists and patients call for better collaboration on adverse drug reactions

European pharmacists and patients welcomed the new proposal for a directive on Pharmacovigilance at an event held on Wednesday 15 September 2010 at the European Parliament as an opportunity for pharmacists and patients to work more effectively together to improve medication safety. The new directive will be adopted by the European Parliament on 21 September and is expected to enter into force by the end of 2010 or in early 2011.

Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry

Diaceutics Limited and London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, announced a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups.

Cancer deaths fall, but prevention still lags behind

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer (the official journal of ECCO - the European CanCer Organisation) on cancer prevention.

Synpromics: Scotland's Latest Biotech Company

Synpromics announces it incorporation as Scotland’s latest biotech company. The new company aims to focus its activities in the area of synthetic mammalian biology and has acquired a number of patent applications that arose out of inventions by its founder and managing director; Dr Michael Leslie Roberts. Synpromics' technology will centre on the development of synthetic promoters for application as research, diagnostic and therapeutic tools.

Research & Development

Inefficient management of chronic pain costs Europe billions of Euros each year

EU-funded study offers hope for stroke sufferers

First DataBank Signs Major New Contract with BT

European pharmacists and patients call for better collaboration on adverse drug reactions

Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry

Cancer deaths fall, but prevention still lags behind

Synpromics: Scotland's Latest Biotech Company

More Pharma News ...